|
DOSAGE
|
1-2 gtts BID to QID, q2hr within 1st 48hrs if needed, then taper. | During the initial 24 to 48 hours, the dosing frequency may be increased if necessary. Care should be taken not to discontinue therapy prematurely
|
|
Cornea SPK (Moderate/Severe) (1) AT 4-8/day + Gel qHS (2) Mild Topical Steroid (FML 0.1% of Lotemax QID) x 1-4 weeks, then taper (3) Add on Restasis BID to QID as alternative or adjunctive treatment (if steroid responder)
|
|
EKC (Viral) with mild SEI: Mild Topical Steroid/gel BID
|
|
Inflammed Ping/PTG (moderate/Severe): (1) UV protection (2) AT 4/day (3) FML 0.1% or Lotemax 0.2% to 0.5% QID (3) NSAID like ketoralac 0.4% or Mast cell combo Pataday qDay to decrease symptoms
|
|
Severe GPC: Short-term use of FML 0.1% or Lotemax 0.2%-0.5% QID (d/c CL wear), addition to topical combo anti-allergies like Pataday 0.2% qDay
|
|
GENERIC
|
prednisolone acetate ophthalmic suspension 0.12%
|
|
INDICATIONS
|
PRED MILD® is indicated for the treatment of mild to moderate noninfectious allergic and inflammatory disorders of the lid, conjunctiva, cornea, and sclera (including chemical and thermal burns).
|
|
Used off label for inflammatory dry eye and as a brief initial adjunctive with Restasis.
|
|
Used off label to reduce inflammatory sequelae of EKC.
|
|
MECHANISM OF ACTION
|
topical anti-inflammatory agent for ophthalmic use
|
|
MICROBIOLOGY
|
Prednisolone acetate is a glucocorticoid. Glucocorticoids inhibit the edema, fibrin deposition, capillary dilation, and phagocytic migration of the acute inflammatory response, as well as capillary proliferation, deposition of collagen, and scar formation.
|
|
CONTRAINDICATIONS & WARNINGS
|
PRED MILD® suspension is contraindicated in acute untreated purulent ocular infections, in most viral diseases of the cornea and conjunctiva including epithelial herpes simplex keratitis (dendritic keratitis), vaccinia, and varicella, and also in mycobacterial infection of the eye and fungal diseases of ocular structures. PRED MILD® suspension is also contraindicated in individuals with known or suspected hypersensitivity to any of the ingredients of this preparation and to other corticosteroids.
|
|
PEDIATRIC USE
|
The safety and effectiveness in pediatric patients have been established. Use in pediatric patients is supported by evidence from adequate and well-controlled studies of prednisolone acetate ophthalmic suspension in adults with additional data in pediatric patients.
|
